Adult T-cell leukemia-lymphoma: Current treatment strategies and novel immunological approaches

Expert Review of Hematology

Volumn 3, Issue 6, 2010, Pages 743-753

  Tanosaki, Ryuji ^a   Tobinai, Kensei ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

adult T cell leukemia lymphoma; graft versus ATL effects; graft versus HTLV 1 effects; hematopoietic stem cell transplantation; human T cell lymphotropic virus type I; IFN ; reduced intensity stem cell transplantation; treatment; zidovudine

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; BORTEZOMIB; BUSULFAN; CARBOPLATIN; CYCLOPHOSPHAMIDE; DACLIZUMAB; DENDRITIC CELL VACCINE; DENILEUKIN DIFTITOX; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FORODESINE; GRANULOCYTE COLONY STIMULATING FACTOR; KW 0761; LENALIDOMIDE; MONOCLONAL ANTIBODY; NITROSOUREA; PENTOSTATIN; PRALATREXATE; PREDNISONE; RANIMUSTINE; SIPLIZUMAB; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; VINDESINE; VORINOSTAT; ZIDOVUDINE; ZONOLIMUMAB;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIVIRAL THERAPY; AUTOTRANSPLANTATION; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CHRONIC LEUKEMIA; CLINICAL TRIAL; COMPETITIVE INHIBITION; CUTANEOUS T CELL LYMPHOMA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FEBRILE NEUTROPENIA; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; MULTIPLE MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; REVIEW; T CELL LEUKEMIA; T CELL LYMPHOMA; THERAPY EFFECT; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; KAPLAN-MEIER ESTIMATE; LEUKEMIA-LYMPHOMA, ADULT T-CELL; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 78649510115     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.10.73     Document Type: Review

References (54)

1. Tobinai K, Watanabe T, Jaffe ES. Human T-cell leukemia virus type-Iassociated adult T-cell leukemialymphoma. In: Non-Hodgkin Lymphoma, Second Edition (Chapter 27). Mauch PM, Armitage JO, Coiffier B, Dalla-Favera R, Harris NL (Eds.), Lippincott Williams & Wilkins, PA, USA, 404-414 (2010).
2. Franchini G. Molecular mechanisms of human T-cell leukemia/lymphotropic virus type I infection. Blood 86(10), 3619-3639 (1995).
3. Matsuoka M, Jeang KT. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat. Rev. Cancer 7(4), 270-280 (2007). Very comprehensive and concise review describing the development of adult T-cell leukemia-lymphoma, including not only molecular mechanisms, but also immunological aspects.
4. Shimoyama M. Chemotherapy of ATL. In: Adult T-cell Leukaemia. Takatsuki K (Ed.). Oxford University Press, Oxford, UK, 221-237 (1994).
5. Taylor GP, Matsuoka M. Natural history of adult T-cell leukemia/lymphoma and approaches to therapy. Oncogene 24(39), 6047-6057 (2005).
6. Tsukasaki K, Hermine O, Bazarbachi A et al. Definition, prognostic factors, treatment and response criteria of adult T-cell leukemia-lymphoma: A proposal from an International Consensus Meeting. J. Clin. Oncol. 27(3), 453-459 (2008). The first international consensus report on the clinical management of patients with adult T-cell leukemia-lymphoma.
7. Kikuchi M, Jaffe ES, Ralfkiaer E. Adult T-cell leukaemia/lymphoma. In: WHO Classification of Tumours; Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Jaffe ES, Harris NL, Stein H et al. (Eds). IARC Press, Lyon, France, 200-203 (2001).
8. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma: A report from the Lymphoma Study Group (1984- 1987). Br. J. Haematol. 79(3), 428-437 (1991).
9. Lymphoma Study Group (1984-1987). Major prognostic factors of patients with adult T-cell leukemia-lymphoma: A cooperative study. Leuk. Res. 15(2-3), 81-90 (1991).
10. Gill PS, Harrington WJ, Kalan MH et al. Treatment of adult T-cell leukemialymphoma with a combination of interferon alfa and zidovudine. N. Engl. J. Med. 332(26), 1744-1748 (1995).
11. Hermine O, Bouscary D, Gessain A et al. Brief report: Treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N. Engl. J. Med. 332(26), 1749-1751 (1995).
12. Takasaki Y, Iwanaga M, Imaizumi Y et al. Long-term study of indolent adult T-cell leukemia-lymphoma. Blood 115(22), 4337-4343 (2010).
13. Ishitsuka K, Ikeda S, Utsunomiya A et al. Souldering adult T-cell leukaemia/ lymphoma: A follow-up study in Kyushu. Br. J. Haematol. 143(3), 442-444 (2008).
14. Bazarbachi A, Plumelle Y, Carlos Ramos J et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J. Clin. Oncol. 28(27), 4177- 4183 (2010).
15. Tobinai K. Clinical trials for human T-cell lymphotropic virus type I-associated peripheral T-cell lymphoma in Japan. Seminar. Hematol. 47(Suppl. 1), 55-57 (2010).
16. Tsukasaki K, Tobinai K, Shimoyama M et al. Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group study (JCOG9109). Int. J. Hematol. 77(2), 64-70 (2003).
17. Yamada Y, Tomonaga M, Fukuda H et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br. J. Haematol. 113(2), 375-382 (2001).
18. Tsukasaki K, Utsunomiya A, Fukuda H et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemialymphoma: Japan Clinical Oncology Group study JCOG 9801. J. Clin. Oncol. 25(34), 5458-5464 (2007). The first Phase III study specifically targeting aggressive adult T-cell leukemia-lymphoma patients, showing the superiority of the vincristine, cyclophosphamide, doxorubicin and prednisone-doxorubicin, ranimustine and prednisone-vindesine, etoposide, carboplatin and prednisone (LSG 15) regimen in comparison with biweekly cyclophosphamide doxorubicin, vincristine and prednisone.
19. Tsukasaki K, Maeda T, Arimura K et al. Poor outcome of autologous stem cell transplantation for adult T cell leukemia/ lymphoma: A case report and review of the literature. Bone Marrow Transplant. 23(1), 87-89 (1999).
20. Sobue R, Yamauchim T, Miyamura K et al. Treatment of adult T cell leukemia with mega-dose cyclophosphamide and total body irradiation followed by allogeneic bone marrow transplantation. Bone Marrow Transplant. 2(4), 441-444 (1987).
21. Ljungman P, Lawler M, Asjo B et al. Infection of donor lymphocytes with human T lymphotrophic virus type 1 (HTLV-1) following allogeneic bone marrow transplantation for HTLV-1 positive adult T-cell leukaemia. Br. J. Haematol. 88(2), 403-405 (1994).
22. Borg A, Yin JA, Johnson PR et al. Successful treatment of HTLV-1- associated acute adult T-cell leukaemia lymphoma by allogeneic bone marrow transplantation. Br. J. Haematol. 94(4), 713-715 (1996).
23. Kawa K, Nishiuchi R, Okamura T, Igarashi H. Eradication of human T-lymphotropic virus type 1 by allogeneic bone-marrow transplantation. Lancet 352(9133), 1034-1035 (1998).
24. Tajima K, Amakawa R, Uehira K et al. Adult T-cell leukemia successfully treated with allogeneic bone marrow transplantation. Int. J. Hematol. 71(3), 290-293 (2000).
25. Tamaki H, Matsuoka M. Donor-derived T-cell leukemia after bone marrow transplantation. N. Engl. J. Med. 354(16), 1758-1759 (2006).
26. Utsunomiya A, Miyazaki Y, Takatsuka Y et al. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 27(1), 15-20 (2001).
27. Okamura J, Uike N, Utsunomiya A, Tanosaki R. Allogeneic stem cell transplantation for adult T-cell leukemia/ lymphoma. Int. J. Hematol. 86(2), 118-125 (2007).
28. Kami M, Hamaki T, Miyakoshi S et al. Allogeneic hematopoietic stem cell transplantation for the treatment of adult T-cell leukemia/lymphoma. Br. J. Haematol. 120 (2), 304-309 (2003).
29. Fukushima T, Miyazaki Y, Honda S et al. Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. Leukemia 19(5), 829-834 (2005).
30. Kato K, Kanda Y, Eto T et al. Allogeneic bone marrow transplantation from unrelated HTLV-I-negative donors for adult T-cell leukemia/lymphoma: Retrospective analysis of data from the Japan Marrow Donor Program. Biol. Blood Marrow Transplant. 13(1), 90-99 (2007).
31. Hishizawa M, Kanda J, Utsunomiya A et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: A nationwide retrospective study. Blood 116(8), 1369-1376 (2010). The largest nationwide retrospective study, including 386 patients, showing the long-term curability of allogeneic stem cell transplantation in spite of its high transplantation-related mortality rate.
32. Okamura J, Utsunomiya A, Tanosaki R et al. Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood 105(10), 4143-4145 (2005).
33. Tanosaki R, Uike N, Utsunomiya A et al. Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia/ lymphoma: Impact of antithymocyte globulin on clinical outcome. Biol. Blood Marrow Transplant. 14(6), 702-708 (2008). Two consecutive Phase I trial of reduced-intensity stem cell transplantation, showing its efficacy and feasibility, and also demonstrating graft-versus-adult T-cell leukemia-lymphoma and human T-cell lymphotropic virus type I effects induced after transplantation.
34. Strauss SJ, Maharaj L, Hoare S et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: Potential correlation of in vitro sensitivity and tumor necrosis factor a response with clinical activity. J. Clin. Oncol. 24(13), 2105-2112 (2006).
35. Matutes E. Adult T-cell leukaemia/ lymphoma. J. Clin. Pathol. 60(12), 1373-1377 (2007).
36. Waldman TA White JD, Goldman CK et al. The interleukin-2 receptor: A target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood 82(6), 1701-1712 (1993).
37. Waldman TA White JD, Carrasquillo JA et al. Radio-immunotherapy of interleukin-2R a expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac. Blood 86(11), 4063-4075 (1995).
38. Osborne GE, Pagliuca A, Ho A et al. Novel treatment of Sezary-like syndrome due to adult T-cell leukemia/lymphoma with daclizumab (humanized antiinterleukin- 2 recepter a antibody). Br. J. Dermatol. 155(3), 617-620 (2006).
39. Kreitman RJ, Wilson WH, White JD et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J. Clin. Oncol. 18(8), 1622-1636 (2000).
40. Di Venuti G, Nawgiri R, Foss F. Denileukin diftitox and hyper-CVAD in the treatment of human T-cell lymphotropic virus 1-associated acute T-cell leukemia/lymphoma. Clin. Lymphoma 4(3), 176-178 (2003).
41. Janik JE, Morris JC, Stetler-Stevenson M et al. Phase I trial of siplizumab in CD2-positive lymphoproliferative disease. J. Clin. Oncol. 23, 174s (2005).
42. Zhang Z, Zhang M, Goldman CK et al. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Res. 63(19), 6453-6457 (2003). (Pubitemid 37255196)
43. Ravandi F, Faderl S. Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin. Leuk. Res. 30(1), 103-105 (2006).
44. Mone A, Puhalla S, Whitman S et al. Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/ IFN-a-refractory adult T-cell leukemia. Blood 106(10), 3380-3382 (2005).
45. d'Amore F, Relander T, Hagberg H et al. HuMax-CD4 (Zanolimumab), a fully human monoclonal antibody: Early results of an ongoing clinical trial in CD4+ peripheral T-cell lymphoma of noncutaneous type. Blood 106, 937a (2005).
46. Callens C, Moura IC, Lepelletier Y et al. Recent advances in adult T-cell leukemia therapy: Focus on a new anti-transferrin receptor monoclonal antibody. Leukemia 22(1), 42-48 (2007).
47. Yamamoto K, Utsunomiya A, Tobinai K et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J. Clin. Oncol. 28(9), 1591-1598 (2010). A Phase I study of anti-CCR4 antibody, showing promising data including sustained complete response in adult T-cell leukemia-lymphoma patients.
48. Yonekura K, Utsunomiya A, Takatsuka Y et al. Graft-versus-adult T-cell leukemia/ lymphoma effect following allogeneic hematopoieteic stem cell transplantation. Bone Marrow Transplant. 41(12), 1029-1035 (2008).
49. Choi I, Tanosaki R, Uike N et al. Long-term outcomes after hematopoietic SCT for adult T-cell leukemia/lymphoma: Results of prospective trials. Bone Marrow Transplant. DOI: 10.1038/bmt.2010.92 (2010) (Epub ahead of print).
50. Abe Y, Yashiki S, Choi I et al. Eradication of virus-infected T-cells in a case of adult T-cell leukemia/lymphoma by nonmyeloablative peripheral blood stem cell transplantation with conditioning consisting of low-dose total body irradiation and pentostatin. Int. J. Hematol. 76(1), 91-93 (2002).
51. Jacobson S, Shida H, McFarlin DE et al. Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature 348(6298), 245-248 (1990).
52. Kannagi M, Harashima N, Kurihara K et al. Tumor immunity against adult T-cell leukemia. Cancer Sci. 96(5), 249-255 (2005). A comprehensive and unique review focusing on the cytotoxic T-lymphocyte response to adult T-cell leukemia-lymphoma cells using animal models.
53. Kurihara K, Harashima N, Hanabuchi S et al. Potential immunogenicity of adult T cell leukemia cells in vivo. Int. J. Cancer 114, 257-267 (2005).
54. Iwanaga M, Watanabe T, Utsunomiya A et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: A nationwide prospective study in Japan. Blood 16(8), 1211-1219 (2010). Results of a follow-up study of asymptomatic human T-cell lymphotropic virus type I carriers, identifying four risk factors for the progression of adult T-cell leukemia-lymphoma.